Table 1. Baseline Patient Demographics and Clinical Characteristics.
| Characteristic | MA-RSV infections, No. (%) | ||
|---|---|---|---|
| Optum integrated dataset (n = 2771) | TriNetX Linked (n = 7442) | Veradigm network EHR linked with claims (n = 57 026) | |
| Age, y | |||
| 18-49 | 627 (22.6) | 4182 (56.2) | 27 917 (49.0) |
| 50-64 | 634 (22.9) | 2218 (29.8) | 17 130 (30.0) |
| 65-74 | 587 (21.2) | 575 (7.7) | 5781 (10.1) |
| ≥75 | 923 (33.3) | 467 (6.3) | 6198 (10.9) |
| Sex | |||
| Male | 1054 (38.0) | 2451 (32.9) | 18 827 (33.0) |
| Female | 1716 (61.9) | 4991 (67.1) | 38 126 (66.9) |
| Unknown | 1 (<0.1) | 0 | 73 (0.1) |
| Payera | |||
| Commercial | 1259 (45.4) | 3721 (50.0) | 27 206 (47.7) |
| Medicare Advantage | 1480 (53.4) | 747 (10.0) | 8376 (14.7) |
| Medicaid | 63 (2.3) | 3084 (41.4) | 20 877 (36.6) |
| Other or unknown | 94 (3.4) | 143 (1.9) | 567 (1.0) |
| Index visit type | |||
| ED | 515 (18.6) | 3060 (41.1) | 20 267 (35.5) |
| Other outpatient | 2256 (81.4) | 4382 (58.9) | 36 759 (64.5) |
| RSV seasons | |||
| 2016-2017 | 344 (12.4) | 625 (8.4) | 6883 (12.1) |
| 2017-2018 | 453 (16.3) | 834 (11.2) | 8683 (15.2) |
| 2018-2019 | 520 (18.8) | 1096 (14.7) | 10 168 (17.8) |
| 2019-2020 | 598 (21.6) | 1240 (16.7) | 9660 (16.9) |
| 2020-2021 | 334 (12.1) | 1644 (22.1) | 7858 (13.8) |
| 2021-2022 | 522 (18.8) | 2003 (26.9) | 13 774 (24.2) |
| Presence of LRTI at Index | |||
| Yes | 1757 (63.4) | 4350 (58.5) | 38 612 (67.7) |
| No | 1014 (36.6) | 3092 (41.6) | 18 414 (32.3) |
| High-risk comorbidities | |||
| Asthma | 832 (30.0) | 2557 (34.4) | 19 081 (33.5) |
| COPD | 846 (30.5) | 1485 (20.0) | 13 159 (23.1) |
| CHF | 675 (24.4) | 1084 (14.6) | 9556 (16.8) |
| Immunocompromised statusb | 552 (19.9) | 1778 (23.9) | 8312 (14.6) |
| Cancer | 529 (19.1) | 1049 (14.1) | 6510 (11.4) |
| Type 2 diabetes | 935 (33.7) | 1989 (26.7) | 17 533 (30.7) |
| Chronic kidney disease | 677 (24.4) | 1118 (15.0) | 9953 (17.5) |
| Pulmonary fibrosis | 143 (5.2) | 230 (3.1) | 1665 (2.9) |
| Cystic fibrosis | 5 (0.2) | 68 (0.9) | 155 (0.3) |
| High-risk subgroup | |||
| Age ≥65 y, asthma, COPD, or CHF | 2027 (73.2) | 3902 (52.4) | 31 497 (55.2) |
| Age ≥75 y, asthma, COPD, or CHF | 1804 (65.1) | 3707 (49.8) | 29 600 (51.9) |
Abbreviations: CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; LRTI, lower respiratory tract infection; MA-RSV, medically attended respiratory syncytial virus.
a
Payer type was assessed on the date of the index visit. Some infections occurred among patients who had more than 1 payer type active on the index visit date.
b
Immunocompromised status includes diagnoses, procedures, and medications for hematologic cancers, conditions of immunodeficiency (including HIV), and organ or stem cell transplants.